Program
donzakimig
Also written as “UCB1381” and “Donzakimig”.
Its studies are mostly in Dermatitis, Atopic, led by UCB.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| UCB | 20 open or running | phase 2since Mar 3, 2022 | Mar 3, 2022 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Mar 3, 2022First study: phase 2 study in Dermatitis, AtopicFirst studyNCT05277571 · 109 enrolled · United States
- Aug 6, 2023Named donzakimigINNProposed as its International Nonproprietary Name in WHO's List 129 · before, UCB1381
- Nov 29, 2024Phase 1 study in Healthy ParticipantsNCT06716879 · 32 enrolled · United States
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06716879Healthy Participants · United States | 1 | Completed | Apr 4, 2025 | 32 |
| NCT05277571Dermatitis, Atopic · United States | 2 | Completed | Jul 17, 2025 | 109 |
How it is read
Names in the registry
- “UCB1381”, 1 entry
- “Donzakimig”, 1 entry
Conditions, from the studies’ own filings
- Dermatitis, Atopic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.